Abstract
Apolipoprotein A-I (apoA-I) is cross-linked and dysfunctional in human atheroma. Although multiple mechanisms of apoA-I cross-linking have been demonstrated in vitro, the in vivo mechanisms of cross-linking are not well-established. We have recently demonstrated the highly selective and efficient modification of high-density lipoprotein (HDL) apoproteins by endogenous oxidized phospholipids (oxPLs), including γ-ketoalkenal phospholipids. In the current study, we report that γ-ketoalkenal phospholipids effectively cross-link apoproteins in HDL. We further demonstrate that cross-linking impairs the cholesterol efflux mediated by apoA-I or HDL3 in vitro and in vivo Using LC-MS/MS analysis, we analyzed the pattern of apoprotein cross-linking in isolated human HDL either by synthetic γ-ketoalkenal phospholipids or by oxPLs generated during HDL oxidation in plasma by the physiologically relevant MPO-H2O2-NO2- system. We found that five histidine residues in helices 5-8 of apoA-I are preferably cross-linked by oxPLs, forming stable pyrrole adducts with lysine residues in the helices 3-4 of another apoA-I or in the central domain of apoA-II. We also identified cross-links of apoA-I and apoA-II with two minor HDL apoproteins, apoA-IV and apoE. We detected a similar pattern of apoprotein cross-linking in oxidized murine HDL. We further detected oxPL cross-link adducts of HDL apoproteins in plasma and aorta of hyperlipidemic LDLR-/- mice, including cross-link adducts of apoA-I His-165-apoA-I Lys-93, apoA-I His-154-apoA-I Lys-105, apoA-I His-154-apoA-IV Lys-149, and apoA-II Lys-30-apoE His-227. These findings suggest an important mechanism that contributes to the loss of HDL's atheroprotective function in vivo.
Highlights
Apolipoprotein A-I is cross-linked and dysfunctional in human atheroma
Based on our recent studies [22], we hypothesized that oxidized phospholipids (oxPLs) modification of Apolipoprotein A-I (apoA-I) can interfere with the cholesterol efflux from cholesterol-loaded cells mediated by apoA-I or high-density lipoprotein (HDL)
Similar results were observed in the intracellular cholesteryl ester loss assay with both HDL3 and apoA-I as cholesterol acceptors (Fig. 3, c and d). These results suggest that the cross-linking of apoproteins by oxPLs could be damaging for the cholesterol efflux mediated by apoA-I and HDL3
Summary
Cross-linking modifications of HDL apoproteins by oxidized phospholipids: structural characterization, in vivo detection, and functional implications. We further demonstrate that cross-linking impairs the cholesterol efflux mediated by apoA-I or HDL3 in vitro and in vivo. We further detected oxPL cross-link adducts of HDL apoproteins in plasma and aorta of hyperlipidemic LDLR؊/؊ mice, including cross-link adducts of apoA-I His-165–apoA-I Lys-93, apoA-I His-154 –apoA-I Lys-105, apoA-I His-154 –apoA-IV Lys-149, and apoA-II Lys-30 –apoE His-227 These findings suggest an important mechanism that contributes to the loss of HDL’s atheroprotective function in vivo. Studies on the effects of short chain reactive aldehydes have demonstrated that only the modification leading to apoA-I cross-linking impaired the capacity of apoA-I to promote cholesterol efflux [7]. To the best of our knowledge, this is the first report on the detection of endogenous oxPLprotein cross-linking adducts and demonstration of their presence in vivo These findings elucidate a novel additional mechanism for in vivo generation of dysfunctional HDL
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.